Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL1 Recombinant Protein (Human/Mouse/Cyno) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CXCL1 Products |
| Gene Delivery | CXCL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CXCL1 Products |
| Benchmark Ab | Anti-CXCL1 Recombinant Antibody Recombinant positive control for assay validation. |
View CXCL1 Products |
| Validator | CXCL1 siRNA Set For knockdown verification in functional assays. |
View CXCL1 Products |
| Related Target A | CXCR2 Primary G-protein coupled receptor for CXCL1, mediating neutrophil chemotaxis. |
View CXCR2 Products |
| Related Target B | CXCL2 Synergistic chemokine sharing CXCR2 receptor, critical for selectivity screening. |
View CXCL2 Products |
| Related Target C | CXCL8 High-affinity CXCR2 ligand; crucial for cross-reactivity and off-target screening. |
View CXCL8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, Mouse (KC), and Cynomolgus CXCL1 proteins available with >95% purity |
| Subfamily counter-screening (CXCL1 vs. CXCL2/8) | Homolog panel proteins strictly verified by mass spectrometry and theoretical MW |
| Lack of positive control references | Sequence-verified clinical benchmark antibodies available |
| Target specificity validation | Sequence-validated siRNA pools for target gene knockdown |
| Functional GPCR conformation maintenance | Lentiviral vectors for stable CXCR2 expression in cell-based assays |
Live CXCL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCL1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination therapies targeting the tumor microenvironment (TME). As first-generation therapies reach the clinic, the next wave of R&D is targeting the CXCR2/CXCL1 axis to overcome immune checkpoint inhibitor (ICI) resistance. Inhibiting CXCL1 prevents the recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment, restoring T-cell mediated anti-tumor immunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Bristol Myers Squibb, Novartis | Solid Tumors, Metastatic Breast Cancer | Affinity & Neutralization Assays (Need high-purity, native-glycosylated CXCL1) |
| Small Molecule (CXCR2 Antagonist) | Dompé Farmaceutici, AstraZeneca | COPD, Metastatic Pancreatic Cancer | Receptor Binding & Calcium Flux (Need CXCR2 stable cell lines via Lentivirus) |
| Bispecific Antibody | Innovent Biologics, Roche | Immuno-oncology Combination | Dual-target binding assays (Need CXCL1 and partner target proteins simultaneously) |